# Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia

> **NCT04106076** · PHASE1 · WITHDRAWN · sponsor: **Cellectis S.A.**

## Conditions studied

- Acute Myeloid Leukaemia

## Interventions

- **BIOLOGICAL:** UCART123

## Key facts

- **NCT ID:** NCT04106076
- **Lead sponsor:** Cellectis S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-07-11
- **Primary completion:** 2019-12-05
- **Final completion:** 2019-12-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The trial was discontinued due to sponsor's decision and not a consequence of any safety concern
- **Last updated:** 2020-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04106076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04106076, "Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04106076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*